The global research antibodies market size is expected to reach USD 5.8 billion by 2028 according to a new study by Polaris Market Research. The report “Research Antibodies Market Share, Size, Trends, Industry Analysis Report, By Product; By Type; By Technologies; By Source; By Application; By End-use; By Region; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The significant factors such as increasing number of R&D activities by the private and government organizations tied with the rising availability of funds offered by the governments for the development of the antibodies may foster the industry growth. In addition, growing incidences of life-threatening and chronic diseases and the widespread of COVID-19 are primarily contributing to the market demand.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/research-antibodies-market/request-for-sample
For instance, in October 2019, Pascal Biosciences Inc. and Y-Biologics declared their partnership with the aim of developing & discovering numerous bio-specific antibodies for Leukemia. Under the agreement, Pascal Biosciences Inc. will use its antibody products and Y-Biologics to share its new antibody platform technology-ALiCE. Therefore, these varieties of company initiatives for technological advancements in developing antibodies are likely to stimulate industry growth.
Major participants such Agilnet Technologies, Abcam Plc, Becton Dickinson & Company, Biolegend, Bio-rad Laboratories, Cell Signalling Technology, Danaher Corporation, F.Hoffman-La Roche, Genscript , Illumina,Lonza Group, Merck Millipore, Perkin Elme Inc, Perkinelmer Roche Ltd., Thermo Fisher.are some of the key players operating in the global market.
There are various players and organizations that are launching new products into the global market for the treatment of death-threatening coronavirus. For instance, in June 2021, Regeneron Pharmaceuticals, Inc. declared the approval of its imdevimab and Regeneron’s casirivimab antibody cocktail for the treatment of mild to moderate COVID-19 patients. This approval was done by Japan’s Ministry of Health, Labor and Welfare (MHLW). This marks the first time the antibody cocktail is recognized as Ronaprev in other nations and REGEN-COVTM in the United States, which has collected complete consent in curing the COVID-19.
Polaris Market Research has segmented the research antibodies market report on the basis of product, type, technology, source, application, end-use and region:
Research Antibodies, Product Outlook (Revenue – USD Million, 2018 – 2028)
Research Antibodies, Type Outlook (Revenue – USD Million, 2018 – 2028)
Research Antibodies, Technology Outlook (Revenue – USD Million, 2018 – 2028)
- Western Blotting
- Flow Cytometry
- Other Technologies
Research Antibodies, Source Outlook (Revenue – USD Million, 2018 – 2028)
- Other Sources
Research Antibodies, Application Outlook (Revenue – USD Million, 2018 – 2028)
- Infectious Diseases
- Stem Cells
- Other Applications
Research Antibodies, End-Use Outlook (Revenue – USD Million, 2018 – 2028)
- Academic & Research Institutes
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies
Research Antibodies, Regional Outlook (Revenue – USD Million, 2018 – 2028)
- North America
- U. S.
- Asia Pacific
- South Korea
- Central & South America
- Middle East & Africa
- Saudi Arabia
- South Africa